Suchen
Climb Bio Inc
CLYMZur Watchlist hinzufügen
12.900USD
-0.390-2.93%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
616.21MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Climb Bio Inc Unternehmen
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Climb Bio Inc Informationen
BörsenkürzelCLYM
Name des UnternehmensClimb Bio Inc
IPO-datumAug 10, 2021
CEOBrennan (Aoife M)
Anzahl der mitarbeiter17
WertpapierartOrdinary Share
GeschäftsjahresendeAug 10
Addresse20 William Street
StadtWELLESLEY HILLS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02481
Telefon18668572596
Websitehttps://climbbio.com/
BörsenkürzelCLYM
IPO-datumAug 10, 2021
CEOBrennan (Aoife M)
Führungskräfte von Climb Bio Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Susan Altschuller, Ph.D.
Dr. Susan Altschuller, Ph.D.
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Climb Bio Inc?
Die fünf größten Anteilseigner von Climb Bio Inc sind: Dr. Aoife M. Brennan
Wie viele Institutionen halten Anteile an Climb Bio Inc (CLYM)?
Mit Stand vom 2026Q1 halten 194 Institutionen Anteile an Climb Bio Inc, mit einem Gesamtmarktwert von etwa 35.98M, was 59.67% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -6593711.00 gestiegen.